ObsEva SA (OBSV) News

ObsEva SA (OBSV): $3.15

-0.01 (-0.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OBSV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter OBSV News Items

OBSV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OBSV News Highlights

  • OBSV's 30 day story count now stands at 15.
  • Over the past 16 days, OBSV's stories per day has been in a clear uptrend, growing by about 2.00 per 8 days.
  • The most mentioned tickers in articles about OBSV are SA, AGE and ABT.

Latest OBSV News From Around the Web

Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.

ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids

(RTTNews) - ObsEva SA (OBSV) said Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options.

Business Insider Markets | September 15, 2021

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -

Intrado Digital Media | September 15, 2021

ObsEva SA: ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive dat

FinanzNachrichten | September 15, 2021

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

Yahoo | September 15, 2021

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

Yahoo | September 15, 2021

ObsEva Files US Application For Linzagolix For Uterine Fibroids

ObsEva SA (NASDAQ: OBSV) has submitted a marketing application to the FDA seeking approval for linzagolix for uterine fibroids. Linzagolix is an oral GnRH receptor antagonist. Related Link: ObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study. The Company believes that if approved, linzagolix will be the only GnRH antagonist in uterine fibroids with a low dose non-add-back therapy (ABT) option. The submission includes 52-week treatment results from the Phase 3 PRIMROSE 1 (th

Yahoo | September 15, 2021

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GENEVA, Switzerland September 7 , 202 1 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23 rd Annual Global Investment Conference to be held September 13-15, 2021.

Intrado Digital Media | September 7, 2021

ObsEva SA: ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GENEVA, Switzerland September 7, 2021 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women''s reproductive health, today

FinanzNachrichten | September 7, 2021

Heavy Menstrual Bleeding (HMB) Market Amazing Demand 3X Revenues by 2021-2028 with ObsEva, AbbVie, Myovant Sciences, Bayer, Enteris BioPharma, Ferring Pharmaceuticals

Heavy menstrual bleeding (HMB) is one of the most common gynecological disorders affecting women of reproductive age. It is subjectively defined as heavy cyclical menstrual bleeding occurring over several consecutive cycles. As observed, it is a total blood loss of

OpenPR | August 30, 2021

7 Hottest Penny Stocks to Pick Up Now

Penny stocks from companies that have reasonable business fundamentals.

Faisal Humayun on InvestorPlace | August 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7231 seconds.